JAK Inhibitors: Impact on Symptoms, Quality of Life, and Patient Outcomes in MF

Srdan Verstovsek, MD, PhD, reviews how treatment with JAK inhibitors improves symptoms, quality of life, and patient outcomes in primary MF.

EP: 1.Introduction: A 52-Year-Old Woman with Intermediate-Risk Primary Myelofibrosis

EP: 2.Clinical Criteria and Tools for Diagnosis of Primary MF

EP: 3.Symptom Scoring Systems and Prognostic Risk Models for MF

EP: 4.Clinical Factors Impacting Risk Assessment, Prognosis, and Progression

EP: 5.Frontline Treatment Options for Primary MF

EP: 6.Efficacy Data from Clinical Trials of Ruxolitinib in Primary MF

EP: 7.Safety Data on Ruxolitinib in Primary MF

Now Viewing

EP: 8.JAK Inhibitors: Impact on Symptoms, Quality of Life, and Patient Outcomes in MF

EP: 9.Benefits of Clinical Trial Enrollment for Patients with MF

EP: 10.Risk of AML and Potential Use of Bone Marrow Transplant in Patients with MF

EP: 11.Considerations for Patient Follow-Up and Management

EP: 12.Remaining Unmet Needs and Future Directions in MF

Recent Videos